JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Iovance Biotherapeutics Inc

Geschlossen

BrancheGesundheitswesen

2.75 -2.83

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.7

Max

2.82

Schlüsselkennzahlen

By Trading Economics

Einkommen

-38M

-116M

Verkäufe

-24M

49M

Gewinnspanne

-235.51

Angestellte

838

EBITDA

-35M

-110M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+228.62% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-224M

945M

Vorheriger Eröffnungskurs

5.58

Vorheriger Schlusskurs

2.75

Nachrichtenstimmung

By Acuity

50%

50%

176 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Iovance Biotherapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Aug. 2025, 23:11 UTC

Ergebnisse

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5. Aug. 2025, 22:45 UTC

Ergebnisse

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5. Aug. 2025, 22:39 UTC

Ergebnisse

Great-West Lifeco Logs Lower 2Q Profit

5. Aug. 2025, 21:32 UTC

Ergebnisse

Coupang Posts Higher 2Q Sales Due to Customer Growth

6. Aug. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6. Aug. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6. Aug. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6. Aug. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5. Aug. 2025, 23:48 UTC

Market Talk

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5. Aug. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5. Aug. 2025, 23:19 UTC

Market Talk

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5. Aug. 2025, 23:03 UTC

Market Talk
Ergebnisse

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5. Aug. 2025, 22:22 UTC

Ergebnisse

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5. Aug. 2025, 22:21 UTC

Ergebnisse

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5. Aug. 2025, 22:20 UTC

Ergebnisse

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5. Aug. 2025, 22:18 UTC

Ergebnisse

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5. Aug. 2025, 22:17 UTC

Ergebnisse

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5. Aug. 2025, 22:17 UTC

Ergebnisse

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5. Aug. 2025, 22:16 UTC

Ergebnisse

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5. Aug. 2025, 22:16 UTC

Ergebnisse

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5. Aug. 2025, 22:15 UTC

Ergebnisse

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5. Aug. 2025, 22:13 UTC

Ergebnisse

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5. Aug. 2025, 22:13 UTC

Ergebnisse

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5. Aug. 2025, 22:12 UTC

Ergebnisse

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5. Aug. 2025, 22:12 UTC

Ergebnisse

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5. Aug. 2025, 21:58 UTC

Ergebnisse

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5. Aug. 2025, 21:30 UTC

Ergebnisse

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5. Aug. 2025, 21:26 UTC

Ergebnisse

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5. Aug. 2025, 21:23 UTC

Ergebnisse

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5. Aug. 2025, 21:17 UTC

Ergebnisse

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Peer-Vergleich

Kursveränderung

Iovance Biotherapeutics Inc Prognose

Kursziel

By TipRanks

228.62% Vorteil

12-Monats-Prognose

Durchschnitt 9.3 USD  228.62%

Hoch 25 USD

Tief 1 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Iovance Biotherapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

6

Buy

4

Halten

1

Sell

Technischer Score

By Trading Central

3.0208 / 3.5Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

176 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.